I now have comprehensive material. Let me compile the full answer.
Thyroid Gland: Anatomy, Physiology, Thyroiditis, Nodules, and Tumours
Sources: Guyton & Hall Medical Physiology | Bailey & Love's Surgery, 28th Ed. | Robbins & Cotran Pathologic Basis of Disease | Schwartz's Principles of Surgery, 11th Ed. | Fischer's Mastery of Surgery, 8th Ed.
1. Anatomy
Gross Anatomy
Figure: Gross and microscopic anatomy of the thyroid gland (Guyton & Hall)
The thyroid gland lies in the anterior neck, straddling the trachea below the larynx. It consists of two lateral lobes connected by a narrow isthmus at the level of the 2nd-3rd tracheal rings. A pyramidal lobe may ascend from the isthmus (a remnant of the thyroglossal duct) in about 50% of people.
Relations:
- Anterolateral: strap muscles (sternohyoid, sternothyroid, omohyoid)
- Posterior: trachea and oesophagus
- Posterolateral: carotid sheath (common carotid artery, internal jugular vein, vagus nerve)
- The space between the thyroid and carotid sheath contains the recurrent laryngeal nerve (RLN), the inferior thyroid artery, and the parathyroid glands
Vasculature:
- Superior thyroid artery (from external carotid) - enters the apex of each lobe
- Inferior thyroid artery (from thyrocervical trunk of subclavian) - the most important, as it runs alongside the RLN
- The inferior thyroid artery and the RLN cross each other in a variable and surgically important relationship
- Thyroid ima artery - inconstant, runs directly from the aorta
- Venous drainage: superior and middle thyroid veins → internal jugular; inferior thyroid veins → brachiocephalic
Lymphatics: drain to prelaryngeal (Delphian node), pretracheal, and deep cervical nodes.
Nerve supply:
- Sympathetic: superior and inferior cervical ganglia (vasoconstriction)
- The recurrent laryngeal nerve is not a thyroid nerve but is intimately related to the gland during surgery - it innervates all intrinsic laryngeal muscles except cricothyroid. Damage causes hoarseness (unilateral) or airway obstruction (bilateral)
- The superior laryngeal nerve (external branch) supplies the cricothyroid muscle and may be damaged during ligation of the superior thyroid artery
Parathyroid glands: typically four, located on the posterior surface of the thyroid. The superior pair lies consistently posterior to the RLN above the inferior thyroid artery crossing. The inferior pair is more variable.
Microscopic Anatomy
The gland is composed of:
- Follicles (100-300 µm diameter): spherical units lined by cuboidal follicular epithelial cells, enclosing a lumen filled with colloid (principally thyroglobulin). These cells are responsible for T3/T4 synthesis.
- Parafollicular C cells: scattered between follicles, produce calcitonin, which lowers plasma calcium. These are the origin of medullary thyroid carcinoma.
- Rich capillary network: thyroid blood flow is ~5× its weight per minute
2. Thyroid Hormone Physiology
Synthesis Pathway
Figure: Thyroid hormone synthesis steps (Guyton & Hall, Fig. 77.2)
Step 1 - Iodide trapping: Iodide (I⁻) is actively transported from blood into the follicular cell via the sodium-iodide symporter (NIS) on the basolateral membrane, co-transporting 2 Na⁺. Energy is derived from the Na⁺/K⁺ ATPase. Normal concentration ratio = 30×; maximally stimulated = 250×.
Step 2 - Iodide transport to colloid: Iodide crosses the apical membrane via pendrin (chloride-iodide counter-transporter) into the follicle lumen.
Step 3 - Thyroglobulin synthesis: Follicular cells synthesize thyroglobulin (MW ~335,000; contains ~70 tyrosine residues) in the ER/Golgi and secrete it into the colloid.
Step 4 - Oxidation and organification: Iodide is oxidised to iodine by thyroid peroxidase (TPO) using H₂O₂. Iodine then attaches to tyrosine residues on thyroglobulin, forming monoiodotyrosine (MIT) and diiodotyrosine (DIT).
Step 5 - Coupling: TPO catalyses coupling: MIT + DIT = T3 (triiodothyronine); DIT + DIT = T4 (thyroxine). T4 is the predominant product.
Step 6 - Secretion: TSH stimulates pinocytosis of colloid, fusion with lysosomes, and proteolytic cleavage of thyroglobulin. Free T3 and T4 are released into the bloodstream. MIT and DIT are deiodinated and the iodide is recycled.
About 50 mg of iodine per year is required for normal hormone production (~1 mg/week). Common table salt is iodised at 1:100,000 to prevent deficiency.
Regulation
- TSH (thyrotropin) from the anterior pituitary is the primary driver of thyroid function - stimulates all steps of synthesis, iodide trapping, and follicular cell growth
- TRH (thyrotropin-releasing hormone) from the hypothalamus stimulates TSH release
- Negative feedback: rising T3/T4 inhibit both TRH and TSH release
T3 vs. T4
| Feature | T4 (Thyroxine) | T3 (Triiodothyronine) |
|---|
| Amount secreted | ~90% | ~10% |
| Peripheral conversion | Deiodination → T3 | Active form |
| Potency | Less active (prohormone) | 3-5× more potent |
| Half-life | ~7 days | ~1 day |
Actions: regulate basal metabolic rate, protein synthesis, cardiac output, thermogenesis, CNS development (critical in foetal/neonatal life), and bone metabolism.
3. Thyroiditis
Thyroiditis encompasses several forms of thyroid inflammation.
3a. Hashimoto's Thyroiditis (Chronic Autoimmune Thyroiditis)
The most common cause of hypothyroidism in iodine-sufficient regions.
Epidemiology: Peak age 45-65 years; female:male = 10:1 to 20:1. Leading cause of non-endemic goitre in children.
Pathogenesis: Autoimmune breakdown of self-tolerance to thyroid antigens. Key mechanisms:
- CD8+ cytotoxic T cells directly destroy follicular cells
- CD4+ Th1 cells release IFN-γ → macrophage activation → follicle damage
- Autoantibodies to thyroglobulin and thyroid peroxidase (TPO) present in the vast majority of patients
- Genetic predisposition: CTLA4, PTPN22, IL2RA gene polymorphisms (shared with other autoimmune diseases)
Pathology: Diffuse gland enlargement (well-demarcated from surrounding structures); pale, yellow-tan cut surface. Histologically:
- Dense mononuclear infiltrate with lymphoid follicles and germinal centres
- Oncocytic (Hürthle cell) change of follicular epithelium - pink, granular cytoplasm
- Follicular atrophy and variable fibrosis
- Classic FNA appearance: oncocytes + heterogeneous lymphocytes
Clinical Features: Usually presents as painless diffuse goitre with hypothyroidism developing gradually. Occasional early transient thyrotoxicosis ("hashitoxicosis") from follicle rupture. As disease progresses: T4/T3 fall, TSH rises compensatorily.
Associations: Type 1 diabetes, Addison's disease, SLE, myasthenia gravis, Sjögren's syndrome. Increased risk of extranodal marginal zone B-cell lymphoma of the thyroid. Possible predisposition to papillary carcinoma (debated).
3b. Subacute Granulomatous Thyroiditis (de Quervain's Thyroiditis)
Aetiology: Follows a viral infection (mumps, Coxsackie, adenovirus).
Clinical: Pain in the neck, fever, malaise, firm irregular goitre. In 10% the onset is acute and very painful with transient hyperthyroidism. In one-third: asymptomatic except for a goitre.
Investigations: Raised inflammatory markers (ESR, CRP), absent thyroid antibodies, serum T4 high-normal or mildly elevated, ¹²³I uptake low (distinguishes from Graves' disease).
Natural course: Self-limiting over several months. Typically: thyrotoxic phase → hypothyroid phase → euthyroid recovery.
Treatment: Prednisone 10-20 mg/day for 7 days, then taper over a month. Thyroxine replacement if hypothyroidism is prominent. Aspirin/NSAIDs for milder cases.
3c. Chronic Lymphocytic (Silent/Painless) Thyroiditis
Similar to Hashimoto's histologically but typically painless and transient. Occurs especially in the postpartum setting (postpartum thyroiditis). Usually self-limiting.
3d. Riedel's Thyroiditis
Very rare (<0.5% of goitres). Thyroid tissue replaced by dense fibrous tissue that infiltrates beyond the capsule into adjacent muscles, parathyroids, RLNs, and carotid sheath. Associated with systemic fibrosclerosis (retroperitoneal fibrosis, mediastinal fibrosis). The gland feels rock hard and fixed - must be distinguished from anaplastic carcinoma by biopsy (wedge of isthmus). Treatment: high-dose steroids, tamoxifen, thyroxine replacement.
4. Thyroid Nodules and the Solitary Nodule
Epidemiology
Palpable thyroid nodules occur in approximately 4% of the US population. Thyroid cancer incidence is ~40 new cases per 1 million. The critical clinical task is identifying which nodules harbour malignancy.
Risk Factors for Malignancy in a Nodule
- History of ionizing radiation exposure (especially childhood radiation for tinea capitis, thymic enlargement, Hodgkin's disease). Risk is maximal 20-30 years post-exposure; 40% of post-radiation nodules are malignant
- Family history of thyroid cancer or associated syndromes (MEN2, Cowden syndrome, FAP)
- Male sex (a nodule in a male carries higher risk)
- Age extremes (very young or elderly)
- Rapid growth, fixation, vocal cord paralysis (hoarseness), dysphagia, cervical lymphadenopathy
Evaluation of the Solitary Thyroid Nodule
History: Duration, growth rate, pain (unusual - raises suspicion for intranodal haemorrhage, thyroiditis, or malignancy), dysphagia, dyspnoea, hoarseness, dull aching pain (suggests MTC), family history, radiation exposure.
Examination: Nodule characteristics, cervical lymph nodes, voice quality, signs of hypo/hyperthyroidism.
Investigations:
-
TSH - first test in all patients. Low TSH → radionuclide scan (functioning/"hot" nodule rarely malignant). Normal/high TSH → proceed to ultrasound.
-
Ultrasound - primary imaging tool. Suspicious features:
- Hypoechoic
- Irregular or ill-defined margins
- Microcalcifications
- Taller-than-wide orientation (in transverse plane)
- Loss of fatty hilum in lymph nodes, peripheral vascularity
-
TI-RADS (Thyroid Imaging Reporting and Data System) by the American College of Radiology - stratifies nodules by risk and guides FNA threshold.
-
Fine-Needle Aspiration Biopsy (FNAB) - the key diagnostic test. Results classified by the Bethesda System:
| Bethesda Category | Diagnosis | Malignancy Risk | Management |
|---|
| I | Non-diagnostic | 1-4% | Repeat FNA |
| II | Benign | 0-3% | Observation |
| III | AUS/FLUS | 10-30% | Repeat FNA or molecular testing |
| IV | Follicular neoplasm | 25-40% | Diagnostic lobectomy or molecular testing |
| V | Suspicious for malignancy | 50-75% | Surgery |
| VI | Malignant | 97-99% | Surgery |
Up to 5% of FNA results are overtly malignant; ~20% are indeterminate (Bethesda III-V).
-
Molecular testing (e.g., ThyroSeq, Afirma) - used for indeterminate Bethesda III/IV nodules to stratify malignancy risk and guide surgical decision-making.
-
Cross-sectional imaging (CT/MRI) - for suspected invasive tumour, retrosternal extension, bulky lymphadenopathy, or compressive symptoms. Pemberton's sign (facial congestion/JVD when arms raised) suggests SVC obstruction from retrosternal goitre.
-
Laryngoscopy - all patients with subjective voice change, prior neck surgery, or suspected posterior extrathyroidal extension.
5. Benign Conditions of the Thyroid Gland
5a. Follicular Adenoma
The most common benign thyroid neoplasm. A solitary, encapsulated lesion of follicular epithelium with a complete fibrous capsule - no capsular or vascular invasion (this distinguishes it from follicular carcinoma on histology). FNA cannot reliably distinguish adenoma from follicular carcinoma - a surgical specimen is needed to assess the capsule.
5b. Toxic Adenoma (Plummer's Disease)
A hyperfunctioning follicular adenoma - produces T3/T4 autonomously. Appears as a "hot nodule" on radionuclide scan. Risk of malignancy is very low. Treatment: radioiodine or surgery.
5c. Multinodular Goitre
Diffuse or nodular enlargement due to follicular hyperplasia, often related to iodine deficiency. May cause compressive symptoms (tracheal deviation, SVC obstruction). Treatment: medical (thyroxine) or surgical (thyroidectomy) for compressive symptoms.
5d. Graves' Disease
The most common cause of endogenous hyperthyroidism. Autoimmune - thyroid-stimulating immunoglobulin (TSI) binds and activates the TSH receptor in ~90% of patients. Classic triad:
- Hyperthyroidism with diffuse goitre
- Infiltrative ophthalmopathy (exophthalmos) - mediated by TSH-receptor antibodies activating retro-orbital fibroblasts → glycosaminoglycan accumulation
- Pretibial myxoedema (infiltrative dermopathy) - minority of patients
Genetic overlap with Hashimoto's (CTLA4, PTPN22, IL2RA polymorphisms; TSHR gene variants specifically). Female:male = 5-10:1; peak 20-50 years. Treatment: antithyroid drugs (carbimazole/propylthiouracil), radioiodine, or thyroidectomy.
6. Malignant Conditions of the Thyroid Gland
Thyroid cancers are predominantly (>95%) well-differentiated and carry an excellent prognosis. They are more common in women (3:1).
Overview of Thyroid Carcinomas
| Type | % of Thyroid Ca | Origin | Prognosis |
|---|
| Papillary | ~80% | Follicular epithelium | Excellent (>95% 10-yr survival) |
| Follicular | ~10-15% | Follicular epithelium | Good (depends on invasion) |
| Hürthle cell | ~3-5% | Follicular epithelium | Intermediate |
| Medullary | ~1-2% | Parafollicular C cells | Intermediate |
| Anaplastic | ~1-2% | Follicular epithelium | Very poor (~100% mortality) |
6a. Papillary Thyroid Carcinoma (PTC)
The most common thyroid malignancy - 80% of all thyroid cancers in iodine-sufficient areas. Predominant cancer in children and radiation-exposed individuals. F:M = 2:1; mean age 30-40 years.
Molecular pathogenesis: Activation of the MAP kinase pathway by mutually exclusive mechanisms:
- BRAF mutation (most common, 40-65%) - V600E variant associated with extrathyroidal extension, lymph node metastasis, and worse prognosis
- RET/PTC rearrangements (10-20%) - especially in children post-radiation
- NTRK1 rearrangements (10-20%)
- RAS mutations (10-30%)
Gross: Hard, whitish; remains flat on sectioning (unlike benign nodules that bulge). Macroscopic calcification, cystic change possible.
Histology: Papillary projections (fronds of fibrovascular stroma covered by neoplastic epithelium), or follicular variant. Diagnosis is based on characteristic nuclear features:
- Pale, glassy nuclei ("ground-glass" or "Orphan Annie eye" nuclei)
- Nuclear grooves
- Intranuclear cytoplasmic inclusions (pseudoinclusions)
- Psammoma bodies - concentric calcified deposits (~40% of cases), representing calcified sloughed cells; virtually pathognomonic when found in a thyroid FNA
Figure: A. Papillary carcinoma histology (H&E). B. FNAB showing Orphan Annie nuclear inclusions (Schwartz's Principles of Surgery)
Multifocality: Present in up to 85% on microscopic examination.
Spread: Characteristically by lymphatics → cervical nodes. "Lateral aberrant thyroid" in a lymph node almost always represents metastatic PTC. Haematogenous spread (to lung, bone) occurs in up to 20% over the course of disease.
Key variant: NIFTP (Non-Invasive Follicular Thyroid Neoplasm with Papillary-like nuclear features) - formerly encapsulated follicular variant of PTC. No capsular invasion; behaves indolently; no longer classified as carcinoma.
Prognosis: >95% 10-year survival. Prognostic systems include AGES, MACIS, AMES, and TNM. High-risk features: age >55, tumour >4 cm, extrathyroidal extension, distant metastases, BRAF V600E mutation, TERT promoter mutation.
Treatment: Total/near-total thyroidectomy for high-risk or bilateral disease; hemithyroidectomy for low-risk, small, unilateral tumours. Central neck dissection for node-positive disease. Post-operative radioactive iodine (RAI) ablation for high-risk patients. Long-term TSH suppression with levothyroxine. Thyroglobulin monitoring for recurrence.
6b. Follicular Thyroid Carcinoma (FTC)
~10-15% of thyroid cancers. More common in iodine-deficient areas. Peak age 40-60 years.
Key distinction from adenoma: Capsular and/or vascular invasion - this can only be assessed on the entire surgical specimen, not by FNA. Hence FNA cannot diagnose FTC.
Molecular: RAS mutations, PIK3CA gain-of-function, PTEN loss-of-function, and the characteristic PAX8-PPAR-γ translocation (found in up to 50%).
Gross: Solitary, well-encapsulated (minimally invasive) or widely invasive tumour replacing the lobe (see image above).
Spread: Characteristically haematogenous to lungs, bone, liver (in contrast to PTC's lymphatic spread). Regional lymph node metastases uncommon.
Prognosis: Variable - minimally invasive (<10% die within 10 years); widely invasive (~50% die within 10 years).
Treatment: Total thyroidectomy. RAI useful as well-differentiated metastases may concentrate radioiodine.
Figure: Follicular thyroid carcinoma (Robbins & Cotran)
6c. Hürthle Cell (Oncocytic) Thyroid Carcinoma
Variant of follicular carcinoma composed of oncocytic (Hürthle/Askenazy) cells. Distinguished by being less likely to take up RAI, making RAI ablation less effective.
6d. Medullary Thyroid Carcinoma (MTC)
Derived from parafollicular C cells; located at the junction of the upper one-third and lower two-thirds of the thyroid parenchyma. Now accounts for ~1-2% of thyroid cancers.
Key features:
- Secretes calcitonin (tumour marker) and often CEA
- 75% sporadic (typically 4th-6th decade); 25% hereditary
- All patients require genetic testing for RET mutations regardless of family history (7% of apparently sporadic cases carry germline mutations)
Hereditary syndromes (RET germline mutations):
- MEN2A (95% of MEN2): MTC + pheochromocytoma + primary hyperparathyroidism - autosomal dominant
- MEN2B: MTC + pheochromocytoma + mucosal neuromas + intestinal ganglioneuromatosis + marfanoid habitus - MTC is often aggressive, presents early
- Familial MTC (FMTC): MTC only, no PHEO or PHPT
Somatic RET mutation in ~50% of sporadic cases.
Workup: Basal calcitonin, CEA, screen for pheochromocytoma (24-hr urine/plasma metanephrines - must be excluded before surgery), serum calcium. Neck ultrasound + FNA. Genetic testing for germline RET.
Histology: Sheets or nests of polygonal to spindle-shaped cells with granular cytoplasm; amyloid deposits in the stroma (from procalcitonin).
Treatment: Total thyroidectomy + central neck dissection. Patients with RET mutations may undergo prophylactic thyroidectomy.
6e. Anaplastic (Undifferentiated) Thyroid Carcinoma (ATC)
The most aggressive thyroid malignancy. Mortality ~100%; mean survival ~6 months. Mean age 65-71 years; 60-70% women.
Pathogenesis: Most arise by dedifferentiation of pre-existing well-differentiated carcinoma (over half have concurrent or prior well-differentiated cancer; >80% have a history of thyroid nodules). Key molecular event: TP53 loss-of-function mutation (not seen in well-differentiated cancers). Also harbours RAS, PIK3CA mutations. Risk factors: prior neck irradiation, iodine deficiency.
Presentation: Rapidly enlarging, bulky, fixed neck mass causing airway obstruction, dysphagia, hoarseness.
Histology: Highly anaplastic cells - large pleomorphic, spindle-shaped cells, or a mixed pattern. Extensive necrosis.
Treatment: Combination of surgery (if resectable), radiotherapy, and chemotherapy. Tyrosine kinase inhibitors (lenvatinib, sorafenib, dabrafenib + trametinib for BRAF-mutated cases). 2021 ATA guidelines guide current management. Death usually results from local invasion and airway compromise rather than distant metastases.
Summary Table: Thyroid Carcinoma Features
| Feature | Papillary | Follicular | Medullary | Anaplastic |
|---|
| Origin | Follicular cells | Follicular cells | C cells | Follicular cells |
| Frequency | 80% | 10-15% | 1-2% | 1-2% |
| Spread | Lymphatic | Haematogenous | Both | Local invasion |
| Key histology | Orphan Annie nuclei, psammoma bodies | Capsular/vascular invasion | Amyloid, calcitonin | Pleomorphic, anaplastic |
| Key mutation | BRAF V600E | PAX8-PPARγ, RAS | RET (germline + somatic) | TP53 loss |
| Tumour marker | Thyroglobulin | Thyroglobulin | Calcitonin, CEA | - |
| RAI uptake | Yes | Yes (well-diff metastases) | No | No |
| Prognosis | Excellent (>95% 10-yr) | Good to fair | Intermediate | Lethal |
Guyton & Hall Textbook of Medical Physiology, Chapter 77 | Bailey & Love's Surgery, 28th Ed., Chapter 55 | Robbins & Cotran Pathologic Basis of Disease, Chapter 24 | Schwartz's Principles of Surgery, 11th Ed., Chapter 38 | Fischer's Mastery of Surgery, 8th Ed., Chapter 34